Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease

Unmet needs in the treatment of psoriasis call for novel therapeutic strategies. Pustular psoriasis and psoriatic arthritis often represent a therapeutic challenge. Focus on IL-36 cytokines offers an interesting approach, as the IL-36 axis has been appointed a critical driver of the autoinflammatory...

Descripción completa

Detalles Bibliográficos
Autores principales: Iznardo, Helena, Puig, Lluís
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122427/
https://www.ncbi.nlm.nih.gov/pubmed/33919434
http://dx.doi.org/10.3390/ijms22094344
_version_ 1783692614704300032
author Iznardo, Helena
Puig, Lluís
author_facet Iznardo, Helena
Puig, Lluís
author_sort Iznardo, Helena
collection PubMed
description Unmet needs in the treatment of psoriasis call for novel therapeutic strategies. Pustular psoriasis and psoriatic arthritis often represent a therapeutic challenge. Focus on IL-36 cytokines offers an interesting approach, as the IL-36 axis has been appointed a critical driver of the autoinflammatory responses involved in pustular psoriasis. Two IL-36R blocking antibodies, imsidolimab and spesolimab, are currently undergoing phase II and III clinical trials, with promising results.
format Online
Article
Text
id pubmed-8122427
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81224272021-05-16 Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease Iznardo, Helena Puig, Lluís Int J Mol Sci Review Unmet needs in the treatment of psoriasis call for novel therapeutic strategies. Pustular psoriasis and psoriatic arthritis often represent a therapeutic challenge. Focus on IL-36 cytokines offers an interesting approach, as the IL-36 axis has been appointed a critical driver of the autoinflammatory responses involved in pustular psoriasis. Two IL-36R blocking antibodies, imsidolimab and spesolimab, are currently undergoing phase II and III clinical trials, with promising results. MDPI 2021-04-21 /pmc/articles/PMC8122427/ /pubmed/33919434 http://dx.doi.org/10.3390/ijms22094344 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Iznardo, Helena
Puig, Lluís
Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
title Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
title_full Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
title_fullStr Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
title_full_unstemmed Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
title_short Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
title_sort exploring the role of il-36 cytokines as a new target in psoriatic disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122427/
https://www.ncbi.nlm.nih.gov/pubmed/33919434
http://dx.doi.org/10.3390/ijms22094344
work_keys_str_mv AT iznardohelena exploringtheroleofil36cytokinesasanewtargetinpsoriaticdisease
AT puiglluis exploringtheroleofil36cytokinesasanewtargetinpsoriaticdisease

Ejemplares similares